Navigation Links
ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
Date:4/15/2008

rug.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk the FDA will determine that ANX-530 and Navelbine are not bioequivalent, including as a result of performing pharmacokinetic equivalence analysis based a patient population other than the population on which ADVENTRX based its analysis; the risk of investigator bias in reporting adverse events as a result of the study's open-label nature, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; difficulties or delays in manufacturing, marketing and obtaining regulatory approval for ANX-530, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-530 and other challenges by patent holders during the Section 505(b)(2) process; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its goals, including funding the c
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
2. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
3. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
4. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
5. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
6. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
7. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
8. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
9. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... September 16, 2014 Cancer ... and Adoptive T-cell Therapies is a new market ... on the three principal types of therapeutics that ... development in cancer immunotherapy (which is often called ... vaccines and Adoptive cellular immunotherapy. , The ...
(Date:9/15/2014)... Sept. 15, 2014  FlexTech Alliance today issued ... printed product demonstrators (demos) and a functional electronic ... with pre-proposals due on October 22, 2014 and ... proposals ultimately selected are provided by the US ... cost share by the proposing organization. ...
(Date:9/15/2014)... a patient has sepsis, a life-threatening condition in which ... often too fast for antibiotics to help. A new ... a team at Harvard,s Wyss Institute for Biologically Inspired ... , "Even with the best current treatments, sepsis ... 30 percent of the time," said Mike Super, Ph.D., ...
(Date:9/15/2014)... of researchers led by Northeastern University has developed ... junctions and a variety of nanocarbon structures in ... easily scalable, which will allow the researchers to ... use in applications ranging from electronic devices to ... to sports equipment. , Their findings were published ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... Cambrex (NYSE:,CBM), a leading life sciences company, announced today ... and Chief Executive Officer,and a member of the Cambrex ... Mack, President and Chief Executive Officer since 1995,and Chairman ... Company will,separate the positions of Board Chairman and CEO ...
... PRINCETON, N.J., May 15 Derma Sciences, Inc.,(OTC Bulletin ... today for the first quarter ended March 31, 2008. ... previous year, including sales,from the newly acquired First Aid ... due primarily to higher than expected,integration costs associated with ...
... supply of top-quality custom cosmesis, hires U.S. ... sales and marketing ... /PRNewswire/ - Touch,Bionics, developer of the i-LIMB Hand, the world,s ... the complete operations of LIVINGSKIN, the developer of the unique,and ...
Cached Biology Technology:Cambrex Appoints Steven M. Klosk as President and CEO 2Derma Sciences Reports First Quarter 2008 Results 2Derma Sciences Reports First Quarter 2008 Results 3Derma Sciences Reports First Quarter 2008 Results 4Derma Sciences Reports First Quarter 2008 Results 5Touch Bionics acquires LIVINGSKIN 2Touch Bionics acquires LIVINGSKIN 3
(Date:9/15/2014)... naturally across all kingdoms of life and constitute a ... of biological activities. The presence of halogen substituents in ... molecular properties. , One of the Holy ... late-stage, site-specific incorporation of a halogen atom into a ... (one of the most inert chemical bonds known in ...
(Date:9/15/2014)... Australia,s leading coral reef ecologists fears that reef biodiversity ... survival that we once thought. , In an international ... Centre of Excellence for Coral Reef Studies (Coral CoE) ... important species within reef ecosystems. , In coral reefs, ... jobs that keep the ecosystem safe and functioning. ...
(Date:9/15/2014)... of Science and Technology in Society in the College ... has won a 2014 National Science Foundation Faculty Early ... of creating a global nuclear emergency response plan. , ... Plant in March 2011 was a turning point in ... Three of the plant,s six nuclear reactors melted down ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2Specialized species critical for reefs 2'Nuclear disasters don't respect national boundaries' 2
... State University have discovered a new method to speed ... advance that could play an important role in making ... an arrayed microchannel reactor and a "laminated architecture" in ... them, are stacked in parallel to provide a high ...
... the first time, completely characterized an important chemical reaction that ... areas. The team,s results indicate that computer models may be ... air quality (smoggy days) by as much as five to ... to people, animals and plants; is the primary ingredient of ...
... made by researchers at the Institut de recherches cliniques ... Noia, Director of the Mechanisms and Genetic Diversity research ... of Experimental Medicine . The team identified a mechanism ... the therapy of some types of lymphoma and leukemia. ...
Cached Biology News:Microreactor speeds nanotech particle production by 500 times 2Study improves accuracy of models for predicting ozone levels in urban areas 2Study improves accuracy of models for predicting ozone levels in urban areas 3Study improves accuracy of models for predicting ozone levels in urban areas 4A discovery could be important for the therapy of lymphoma and leukemia 2
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...
...
... a fast, easy to use, reproducible and ... are 15 times faster and 5 times ... 5%). ,The VoluPAC tubes enable the determination ... a cell suspension, resulting in absolute data ...
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
Biology Products: